Prestige Consumer Healthcare Inc. · NYSE:PBH
Prestige Consumer Healthcare — Q1 2026 Earnings Presentation
17 slides from Prestige Consumer Healthcare's earnings presentation, Aug 7, 2025
Slide 1: First Quarter FY 2026 Results
First Quarter FY 2026 Results August 7th, 2025
Slide 2: Safe Harbor Disclosure
Safe Harbor Disclosure This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including revenues, organic revenue growth, diluted EPS, and f
Slide 3: Agenda for Today’s Discussion
Agenda for Today’s Discussion I. Performance Update II. Financial Overview III. FY 26 Outlook FIRST QUARTER FY 26 RESULTS 3
Slide 4: I. Performance Update
I. Performance Update FIRST QUARTER FY 26 RESULTS
Slide 5: Q1 FY 26 Performance Update
Q1 FY 26 Performance Update ◼ Quarterly Revenue of $249.5 million, decline driven primarily by Eye Care supply Q1 FY 26 Sales ◼ As expected, revenue also impacted by Q4 customer order timing Drivers ◼ Eye care impact partially offset by continued International segment growth ◼ Gross Margin of 56.2%,
Slide 6: Securing Long-Term Eye Care Capacity
Securing Long-Term Eye Care Capacity Eye Care Supply Chain Impact Strategic Initiatives ◼ Eye Care supply chain significantly impacted ◼ Announcing strategic acquisition of Pillar5 to shipments in Q1 secure and expand long-term eye care capacity ◼ Key supplier maintenance in May unexpectedly ◼ Addit
Slide 7: II. Financial Overview
II. Financial Overview FIRST QUARTER FY 26 RESULTS
Slide 8: Q1 FY 26 Performance Highlights
Q1 FY 26 Performance Highlights (6.6%) Revenue of $249.5 million, down 6.4% vs. prior year excluding foreign currency(1) $267.1 $249.5 (0.0%) $79.6 $79.7 EBITDA(2) of $79.6 million flat vs. prior year 5.6% $0.95 $0.90 Diluted EPS of $0.95 up 5.6% vs. adjusted (2) prior Revenue EBITDA (2) Adj. Dilute
Slide 9: Q1 FY 26 Consolidated Financial Summary
Q1 FY 26 Consolidated Financial Summary 3 Months Ended Comments Q1 FY 26 Q1 FY 25 % Chg ◼ Organic Revenue(1) down 6.4% vs. prior year Total Revenue $ 249.5 $ 267.1 (6.6%) – Driven by Clear Eyes supply constraints Gross Profit 140.3 146.0 (3.9%) % Gross Margin 56.2% 54.7% – International segment up ~
Slide 10: Record Free Cash Flow and Anticipated Acquisition Terms
Record Free Cash Flow and Anticipated Acquisition Terms Free Cash Flow Comments Pillar5 Acquisition Q1 FY 26 Q1 FY 25 ◼ Solid Q1 Free Cash Flow(2) of ◼ Entered agreement to acquire $78.2 million current Clear Eyes supplier 45.8% Pillar5 Pharma – Attributable to the timing of working capital and ◼ Pu
Slide 11: III. FY 26 Outlook
III. FY 26 Outlook FIRST QUARTER FY 26 RESULTS
Slide 12: Updating FY Outlook
Updating FY 26 Outlook ◼ Update in guidance due largely to ongoing eye care supply constraints in first half ◼ Continue to benefit from well-diversified portfolio and brand-building playbook Top Line Trends ◼ Revenues of $1,100 to $1,115 million — Expected organic revenue down approximately (1.5%) t
Slide 13: Q&A
Q&A FIRST QUARTER FY 26 RESULTS
Slide 14: Appendix
Appendix (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measures in the attached Reconciliation Schedules and / or our earnings release dated August 7, 2025 in the “About Non-GAAP Financial Measures” section. (2) EBITDA & EBITDA Margi
Slide 15: Reconciliation Schedules
Reconciliation Schedules Organic Revenue Change Three Months Ended June 30, 2025 2024 (In Thousands) GAAP Total Revenues $ 249,530 $ 267,142 Revenue Change (6.6%) Adjustments: Impact of foreign currency exchange rates - (670) Total adjustments $ - $ (670) Non-GAAP Organic Revenues $ 249,530 $ 266,47
Slide 16: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Adjusted Diluted EPS Three Months Ended June 30, 2025 2024 Net Diluted Net Diluted Income EPS Income EPS (In Thousands, except per share data) GAAP Net Income and Diluted EPS $ 47,466 $ 0.95 $ 49,068 $ 0.98 Adjustments: Normalized tax rate adjustment(a) - - (4,03
Slide 17: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Projected Free Cash Flow (In millions) Projected FY'26 GAAP Net Cash provided by operating activities $ 255 Additions to property and equipment for cash (10) Projected FY'26 Non-GAAP Free Cash Flow $ 245 FIRST QUARTER FY 26 RESULTS 17
Prestige Consumer Healthcare — Q1 2026 Earnings Presentation on 6ix